Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Spectral Diagnostics has expanded its relationship with Toray Medical for the marketing and sale of the company's Endotoxin Activity Assay, the FDA cleared assay for the measurement of endotoxin.
Subscribe to our email newsletter
Under the terms of the new collaboration agreement, Spectral will have access to Toray’s distributors in new geographic territories including China, India, Russia and Canada for the sales and promotion of Endotoxin Activity Assay (EAA) in combination with its Toraymyxin blood purification device, which removes endotoxin from the bloodstream. These distributors will also market and sell the EAA diagnostic as a stand-alone product.
Toray and Spectral will work together to commercialize EAA and Toraymyxin through the distributors, including holding jointly sponsored marketing events. Various distribution agreements related to this arrangement are expected to be finalized over the remainder of Spectral’s 2008 fiscal year.
Paul Walker, president and CEO of Spectral, said: “This expansion of our collaboration with Toray will strengthen our presence in additional geographic territories, a key component in the global commercialization strategy for our EAA product. The arrangement further highlights the benefits of using EAA to identify patients most likely to benefit from anti-endotoxin therapies.”